<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Meta-analyses of clinical trials suggest that the use of the thiazolidinedione (TZD), <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> may increase the risk of myocardial ischaemic events by 30-40% </plain></SENT>
<SENT sid="1" pm="."><plain>Although these controversial data must be interpreted with caution, in the absence of definitive prospective cardiovascular (CV) outcomes data, they represent a prominent source of evidence concerning the CV safety of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The results of meta-analyses and a large randomized-controlled CV outcomes trial provide strong evidence that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> does not increase the risk of coronary events </plain></SENT>
<SENT sid="3" pm="."><plain>This article clarifies the clinical significance of these meta-analytical findings alongside other sources of evidence and assesses their impact on evolving treatment guidelines and recommendations for the use of TZDs in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>